US equities |
MU $953.19 ▼-3.62% NVDA $228.52 ▲+0.97% META $762.50 ▲+2.63% AAPL $341.27 ▲+0.09% MSFT $543.45 ▲+0.43% SNDK $1,482.33 ▼-0.34% AMD $605.53 ▲+1.90% SPCX $156.54 ▼-4.21%
FinancialContent

Freenome, Inc. - Common stock (NQ:FRNM)

12.64 -0.58 (-4.39%)
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Freenome, Inc. - Common stock

News headline image
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
From Freenome, LLC
Via GlobeNewswire
News headline image
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
Investigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening 
From Freenome, Inc.
Via GlobeNewswire
News headline image
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
From Freenome, Inc.
Via GlobeNewswire